Chronic myeloid leukemia on imatinib with recurrent sub-dural haemorrhage

Ambati Bhavani; Palanki Satya Dattatreya; Vinukonda Shyamala

doi:10.18203/2320-6012.ijrms20214729

Authors

Ambati Bhavani Department of Medical Oncology, Omega Hospitals, Hyderabad, Telangana, India
Palanki Satya Dattatreya Department of Medical Oncology, Omega Hospitals, Hyderabad, Telangana, India
Vinukonda Shyamala Department of Medical Oncology, Omega Hospitals, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20214729

Keywords:

Chronic myeloid leukemia, Imatinib, Subdural hemorrhage

Abstract

Imatinib is an FDA approved first-line treatment for Philadelphia-positive CML. It is a selective tyrosine kinase inhibitor specifically targeting BCR-ABL, c-KIT, PDGFRA. It has been reported with low incidence of adverse effects and high tolerability, with haemorrhagic events being a rare complication. We report here a case of 51-year-old female patient with chronic myeloid leukemia who was on high dose imatinib experienced recurrent sub-dural haemorrhage. This case report emphasizes on the need to consider Sub dural haemorrhage as an unusual cause of headache associated with vomiting in a patient taking high dose of imatinib.

Metrics

Metrics Loading ...

References

Nash I. Chronic myeloid leukemia. N Engl J Med. 1999;341:765.

O'Brien SG, Guilhot F, Larson RA. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.

Chen JC, Levy ML. Causes, epidemiology, and risk factors of chronic subdural hematoma. Neurosur clin North Am. 2000;11(3):399-406.

Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. ASH Education Program Book. 2001;2001(1):87-112.

Song KW, Rifkind J, Al-Beirouti B. Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma. 2004;45:1633-6.

Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114:261-3.

Matsue K, Aoki T, Odawara J, Kimura S, Yamakura M, Takeuchi M. Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Leuk Res. 2009;33:867-9.

Okajima K, Kohno I, Tsuruta J, Okabe H, Takatsuki K, Binder BR. Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancer. Thromb Res. 1992;66:717-27.

Kluft C, Vellenga E, Brommer EJ, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood. 1982;59:1169-80.

Favier R, Aoki N, de Moerloose P. Congenital alpha (2)-plasmin inhibitor deficiencies: a review. Br J Haematol. 2001;114:4-10.